DiaMedica Therapeutics (DMAC) Interest & Investment Income (2019 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Interest & Investment Income came in at -$11000.0 in Q2 2026, up 42.11% on a YoY basis from -$7740.7 in Q2 2025, and up 85.53% quarter-over-quarter from -$76000.0 in Q1 2026.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Interest & Investment Income (2019 - 2026) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Interest & Investment Income for 8 consecutive years, with -$11000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest & Investment Income rose 42.11% year-over-year to -$11000.0; the trailing twelve-month figure through Jun 2026 stood at $825000.0 (down 26.6% YoY), and the FY2025 full-year result was $1.7 million, down 27.47% from the prior year.
- Interest & Investment Income grew to -$11000.0 in Q2 2026 per DMAC's latest filing, from -$76000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.0 million in Q4 2023 and bottomed at -$76000.0 in Q1 2026.
- Historically, Interest & Investment Income has averaged $212222.2 across 5 years, with a median of -$11500.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income tumbled 6100.0% in 2022, then surged 2177.27% in 2023.
- Over 5 years, Interest & Investment Income stood at $88000.0 in 2022, then soared by 2177.27% to $2.0 million in 2023, then sank by 72.9% to $543000.0 in 2024, then decreased by 13.08% to $472000.0 in 2025, then plunged by 102.33% to -$11000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$11000.0, -$76000.0, and $472000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.70 Bn | 195.71 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.26 Bn | 177.08 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.36 Bn | 124.51 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.46 Bn | 74.47 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 61.27 Bn | 56.09 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 53.85 Bn | 48.71 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.74 Bn | 30.43 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.62 Bn | 30.33 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.54 Bn | 29.54 Bn | 1.16 Mn | 36.92 Mn |
| 10 | DiaMedica Therapeutics | 346.81 Mn | 346.81 Mn | - | -11,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11,000.00 |
| Mar 31, 2026 | -76,000.00 |
| Dec 31, 2025 | 472,000.00 |
| Sep 30, 2025 | 440,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Mar 31, 2025 | -18,000.00 |
| Dec 31, 2024 | 543,000.00 |
| Sep 30, 2024 | 618,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2023 | -64,000.00 |
| Jun 30, 2023 | -34,000.00 |
| Mar 31, 2023 | 45,000.00 |
| Dec 31, 2022 | 88,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | -60,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Dec 31, 2021 | -46,000.00 |
| Sep 30, 2021 | -2,000.00 |